Yet another study has been published showing that patients receiving care at PE-owned hospitals experienced a higher rate of hospital-acquired adverse events, like infections and falls, than patients receiving care at hospitals that are not PE-owned. The research comes as concerns about PE-owned hospitals are intensifying — from leaders both within and outside of the healthcare industry.
This week, two bipartisan members of the Senate Budget Committee launched an investigation into private equity and its impact on healthcare. They initiated the probe to get answers about “questionable financial transactions” that could be hurting care quality for patients at hospitals owned by private equity firms.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
In an interview, Nathan Ray, a partner with the healthcare and life practice who oversees M&A/PE related work in that industry for West Monroe, highlighted how his firm works with companies to drive due diligence for clients, and help acquired companies address issues and differentiate during holds.
Baxter International is selling its biopharma solutions business to private equity firms. The transaction is part of a broader trend in which life science firms are spinning out or selling operations in order to hone the focus of the remaining business on certain areas.
The volume of healthcare deals has increased in 2022, driven in large part by private equity, according to a new PwC report. But deal values have been declining, a trend that is expected to continue into 2023.
Private equity’s expanding presence in urgent care and the consolidation of the industry raise concerns about the quality and affordability of care, according to a recent report. It argued that the industry should be wary about this ownership trend, as private equity firms could cut staff, push costly procedures and strip out assets from providers.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Independent physician practices are being gobbled up by hospitals, payers and private equity, and while some see it as a boon for the practices and industry as a whole, others believe it will raise costs and block access to care.
The Covid-19 pandemic spurred the rate of physician practice acquisition by hospitals and corporate entities, like payers and private equity firms, a new report shows. As a result, by January 2021, about 48% of physician practices across the country were owned by one or the other entity.
Amid a heated battle over an ownership change, Prospect Medical Holdings has threatened to close two of its hospitals in Rhode Island in response to conditions the state's attorney general proposed. The hospital chain's private equity owner is looking to sell its majority stake but requires state approval to move forward.
Hospitals acquired by PE firms tend to have higher operating margins than those that are not acquired — and that gap widens over time, a new study shows. But it is too early to say whether these glowing financial figures equate to better support for clinical care.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Private equity firm Accelmed recently closed an oversubscribed, $400 million fund. The firm primarily invests in health-tech startups, such as its recent investment in medication adherence company MedMinder.
A Bass Berry & Sims-hosted panel looks back at 2020 and forward to 2021.
Pamela Aldsworth, head of VC coverage and managing director at J.P. Morgan, discusses deals and dealmaking during the pandemic and how startups can survive, in a special presentation to mark MedCity News' annual INVEST conference.
A key component of the deal includes a $1 billion purchase of 50% of royalties owed to Alnylam on sales of inclisiran, a drug for hypercholesterolemia that works by gene silencing. The company's CEO said uncertainty and volatility due to Covid-19 meant the timing was right for the deal.
Financial terms of the deal were not disclosed. However, Thread said it would use the investment - from JLL Partners and Water Street Healthcare Partners - to accelerate the expansion of its service offering globally.